9,21,22,27,28 AMPLITUDE-O, a trial that studied efpeglenatide, disclosed a reduction in the composite kidney outcome by 32% relative to placebo in people with type 2 diabetes and a history of heart or kidney disease
The most useful next step is usually a candid review of treatment fit, not a rushed decision based on convenience alone
This suggests that Epitalon may not just restore telomere length through enzymatic activation, but it may actually reprogram the transcriptional readiness of cells, shifting their expression profiles toward a more youthful state
But more importantly, it is preventable
It is not approved for any medical use in the UK